To the Editor We agree with the recent Viewpoint1 suggesting that exemption to the X-waiver, while an important step to increase access to buprenorphine, likely will not sufficiently address barriers to access of medications for opioid use disorder (MOUD). The Viewpoint authors acknowledged both disparities in access to MOUD and in overdose deaths, especially among rural communities and Black individuals. However, it is unclear if increased physician education and reduced regulatory barriers for physicians prescribing MOUD will address these discrepancies. Moreover, we are concerned that policy changes that increase the number of buprenorphine prescribers without addressing the structural causes of these disparities may have the unintended consequence of reinforcing or increasing them.
Shearer RD, Ford BR, Howell BA. X-Waiver Exemption in the Treatment of Opioid Use Disorder. JAMA. 2021;326(5):441–442. doi:10.1001/jama.2021.8267
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: